吴宝剑，男，博士，药剂学教授，博士生导师。分别于2004年、2007年和2011年获药学学士、复旦大学药剂学硕士及美国（University of Houston）药剂学博士学位。博士毕业后      在美国（Baylor College of Medicine）进行博士后研究（生物化学与分子生物学）。2012年9月回国，在从事教学和科研工作。发表学术论文50余篇，其中SCI收录论文41篇。
药物新剂型、药物吸收与代谢及药代动力学。1.DongD.(2012)Humanglutathionetransferases:structure,function,and drug dis-covery. .33(12):656-668.(IF:9.3) 　　2.LiS,DongD.(2013)3Dstructuresandligandspecificitiesofnuclearxenobiotic receptorsCAR,PXR,andVDR..18(11-12):574-81.(IF:6.6) 　　3.(2011)Substrateinhibitionkineticsindrugmetabolismreactions. 43(4):440-456.(IF:5.5) 　　4.DongD,,ChowD,HuM(2012)Substrateselectivityofhumancytochrome p450spredi-cted fromcrystalstructuresandinsilicomodeling..44(2):192-208.(IF:5.5) 　　5.ZhouX,MaZ,DongD,(2013)ArylamineN-acetyltransferases:AStructural Perspec-tive. .169(4):748-60.(IF:5.1) 　　6.WangX,ZhangS,HuM(2012)Accuratepredictionofglucuronidationof structurally diversephenolicsbyhumanUGT1A9usingcombinedexperimentaland insilicoapproaches. .29(6):1544-1561.(IF:4.7)（封面论文） 　　7.JiangW,YinT,GaoS,HuM(2012)Anewstrategytorapidlyevaluate kineticsof glucuronideeffluxbyBCRP/ABCG2..29(11):3199-3208.(IF:4.7) 　　8.XuB,HuM(2011)Regioselectiveglucuronidationofflavonolsbysixhuman UGT1A isoforms.28(8):1905-1918.(IF:4.7) 　　9.ZhangX,HuM(2011)Evaluationof3,3’,4’-trihydroxyflavoneand3,6,4’-trihydro-xyflavone(4’-O-glucuronidation)astheprobesubstratesforhepaticUGT1A1.. 8(6): 2379-2389.(IF:4.6) 　　10.BasuS,MengS,WangX,HuM(2011)Regioselectivesulfationand glucuronidation ofphenolics:insightsintothestructuralbasis..12(9):900-916.(IF: 4.4) 　　11.MorrowJK,SinghR,ZhangS,HuM(2011)3D-QSARstudiesonUGT1A9-mediated3-O-glucuronidationofflavonolsusingapharmacophore-basedCOMFAmodel. . 336(2):403-413.(IF:3.9) 　　12.DongD,HuM,ZhangS*(2013)Quantitativepredictionofglucuronidation in humans usingtheinvitro-invivoextrapolationapproach..13(11):1343-52.(IF:3.7) 　　13.DengD,LuY,WuW(2008)Biphasicreleaseofindomethacinfrom HPMC/pectin/calcium matrixtablet:II.Influencingvariables,stabilityand pharmacokineticsindogs. .69(1):294-302.(IF:3.8). 　　14.ChenZ,WeiX,SunN,LuY,WuW(2007)Biphasicreleaseof indomethacinfrom HPMC/pectin/calciummatrixtablet:I.Characterizationand mechanisticstudy..67(3):707-714.(IF:3.8) 　　15.MaZ,LiuH，(2013)Structure-baseddrugdesignofcatechol-O-methyltransferase inhibitorsforCNSdisorders.:10. 1111/bcp.12169.(IF:3.6). 　　16.(2011)PharmacokineticinterplayofphaseIImetabolismandtransport: atheoretical study..101(1):381-393.(IF:3.1). 　　17.(2012)Useofphysiologicallybasedpharmacokineticmodelstoevaluate theimpact ofintestinalhydrolysisofglucuronideonthepharmacokineticsof aglycone.101(3):1281-1301.(IF:3.1). 　　18.KulkarniK,BasuS,ZhangS,HuM(2011)First-passmetabolismviaUDP-glucuronosyl transferase:abarriertooralbioavailabilityofphenolics.. 100(9):3655-3681. (IF:3.1). 　　19.DongD,(2012)InsilicomodelingofUGT1A10substratesusingthe VolSurfapproach. 101(9):3531-3539.(IF:3.1). 　　20.LiJ，MaZ，JiangR，（2013）Hormone-relatedpharmacokineticvariations associated withanti-breastcancerdrugs.9(9):1085-95.(IF:2.9). 　　21.DongD,AkoR,(2012)Crystalstructuresofhumansulfotransferases: insightsinto themechanismsofactionandsubstrateselectivity.8(6):635-646.(IF:2.9). 　　22.LuD,ZhangJ,YangZ,LiuH,LiS,MaZ*(2013)Quantitativeanalysis of Cistan-ches HerbausingHPLC-DAD-HRMScombinedwithchemometricmethods..36(12):1945-52.(IF:2.6). 　　23.LiuW,LiuH,SunH,DongD,MaZ,WangY,(2013)MetaboliteElucidation ofthe Hsp-90 InhibitorSNX-2112UsingUltraperformanceLiquidChromatography/QuadrupoleTime-of-flightMassSpectrometry(UPLC-QTOF/MS).(已接收)(IF:2.0) 　　24.AkoR,DongD,(2012)3D-QSARstudiesonUDP-glucuronosyltransferase2B7 substrates usingthepharmacophoreandVolSurf approaches..42(9):891-900.(IF:2.0) 　　25.LiuH,MaZ,(2013)Structure-activityrelationshipsandinsilicomodelsofP-glycoprotein(ABCB1)inhibitors..43(11):1018-26.(IF:2.0) 　　26.DongD,AkoR,HuM,(2012)UnderstandingSubstrateSelectivityof HumanUDP-glucur-onosyltransferasesthroughQSARmodelingandanalysisofthehomologous enzymes. . 42(8):808-820.(IF:2.0) 　　27.ShunN,WeiX,WuW(2007)Characterizationof5-fluorouracilreleasefrom hydroxy-propyl methylcellulosecompression-coatedtablets.. 12(2):203-210.(IF:1.3).
1.国家自然科学基金面上项目：植物糖基转移酶高表达工程菌减轻抗癌药伊立替康毒性研究 （81373496）， 起止时间：2014.1-2017.12。（75万元，主持）。　　2.广州市珠江科技新星人才计划（30万元，主持）。1.Methodsformakingandusingdrugdetoxifyingbacteria.（美国专利申请号:61/583,711） 　　2.一种间苯三酚口腔崩解片及其制备方法。（专利号:200710172518.3） 　　3.一种用于结肠定位给药的在体交联包芯片。（专利号:200610029476.3）1.杂志编委　　JournalofPharmacologyResearch;JournalofSingleCellGenomics&Proteomics 　　2.美国药学科学家协会（AAPS）会员 　　3.美国药理学与实验治疗学会（ASPET）会员 　　4.美国OMICSGroup会员 　　5.SCI杂志审稿人 　　MolecularPharmaceutics;BritishJournalofPharmacology;PLoSONE;Foodand Chemical Toxicology; Xenobiotica;JournalofPharmacyandPharmacology; InternationalJournal ofNanomedicine; CurrentPharmaceuticalAnalysis; Biopharmaceutics&DrugDisposition; üInternationalJournalofMolecularSciences; AnalyticalBiochemistry;CurrentMedicinal Chemistry;BioMedResearchInternational;Mini-ReviewsinMedicinalChemistry等暨南大学复旦大学休斯敦大学贝勒医学院暨南大学药学院  